Compare Amgen, Inc. (AMGN) vs Commvault Systems Inc (CVLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Commvault Systems Inc — how do they compare? Amgen, Inc. trades at $360.87 (market cap $196.12B), while Commvault Systems Inc trades at $145.5 (market cap $6.24B). The key difference: Amgen, Inc. is far larger — about 31.4× Commvault Systems Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Commvault Systems Inc pays none. Which is the better fit depends on your goals.
| AMGN | CVLT | |
|---|---|---|
Market Cap | $196.12B | $6.24B |
Sector | Health | Technology |
52-Week High | $388.16 | $195.41 |
52-Week Low | $271.18 | $75.18 |
Enterprise Value | $241.41B | $6.25B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Commvault (CVLT) trades at $150.57, down 0.57% on the day, with a bullish technical signal from moving averages and strong support at $146. The company reported revenue of $995.62M in 2025, with net income of $76.11M, though earnings have been mixed with two beats and one miss in recent quarters. A high P/E of 95.3 indicates premium valuation, while ROE stands at 42.49%. Recent news highlights a securities class action lawsuit with a July 17, 2026 deadline.
Outlook is mixed: analyst consensus is bullish with 54.55% buy ratings and a $128.75 price target, but legal risks and high valuation pose headwinds. Revenue growth to $1.2B in 2026 offers upside, yet profit margin compression and lawsuit uncertainty require caution for investors seeking stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Commvault Systems Inc
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →
